ITRM
Iterum Therapeutics plc
Biotechnology
Market Cap$2M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ITRM vs IQV
Revenue, margins, valuation, and 5-year total return — side by side.
IQV
IQVIA Holdings Inc.
Medical - Diagnostics & Research
Market Cap$29.95B
5Y Perf.+14.1%
ITRM vs IQV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ITRM | IQV |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $2M | $29.95B |
| Revenue (TTM) | $390K | $16.63B |
| Net Income (TTM) | $-27M | $1.39B |
| Gross Margin | -171.3% | 26.1% |
| Operating Margin | -52.0% | 13.9% |
| Forward P/E | — | 13.9x |
| Total Debt | $46M | $16.17B |
| Cash & Equiv. | $24M | $1.98B |
ITRM vs IQV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ITRM
IQV
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Iterum Therapeutics… (ITRM) | 100 | 0.0 | -100.0% |
| IQVIA Holdings Inc. (IQV) | 100 | 114.1 | +14.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ITRM vs IQV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IQV leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Iterum Therapeutics plc is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
ITRM
Iterum Therapeutics plc
The Growth Play
ITRM is the clearest fit if your priority is growth exposure.
- EPS growth 57.4%
- 14.8% revenue growth vs IQV's 5.9%
Best for: growth exposure
IQV
IQVIA Holdings Inc.
The Income Pick
IQV carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 2 yrs, beta 1.33
- 167.5% 10Y total return vs ITRM's -100.0%
- Lower volatility, beta 1.33, current ratio 0.75x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ITRM | 14.8% revenue growth vs IQV's 5.9% |
| Quality / Margins | IQV | 8.3% margin vs ITRM's -69.1% |
| Stability / Safety | IQV | Beta 1.33 vs ITRM's 1.49 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IQV | +20.7% vs ITRM's -96.9% |
| Efficiency (ROA) | IQV | 4.7% ROA vs ITRM's -74.8%, ROIC 8.7% vs -117.8% |
ITRM vs IQV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ITRM vs IQV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIQVLAGGINGITRM
ITRMIterum Therapeutics p…
1leads
IQVIQVIA Holdings Inc.
4leads
6 Total Categories
CATEGORYLEADERvs ITRMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IQV4/5
Valuation MetricsMultiples, price ratios, and targets
ITRM1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IQV5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IQV6/6
Risk & VolatilityBeta, volatility, and downside exposure
IQV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IQV leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV is the larger business by revenue, generating $16.6B annually — 42646.2x ITRM's $390,000. IQV is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to ITRM's -69.1%.
| Metric | ITRMIterum Therapeuti… | IQVIQVIA Holdings In… |
|---|---|---|
| RevenueTrailing 12 months | $390,000 | $16.6B |
| EBITDAEarnings before interest/tax | -$19M | $3.5B |
| Net IncomeAfter-tax profit | -$27M | $1.4B |
| Free Cash FlowCash after capex | -$20M | $2.7B |
| Gross MarginGross profit ÷ Revenue | -171.3% | +26.1% |
| Operating MarginEBIT ÷ Revenue | -52.0% | +13.9% |
| Net MarginNet income ÷ Revenue | -69.1% | +8.3% |
| FCF MarginFCF ÷ Revenue | -51.1% | +16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +8.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +33.3% | +15.0% |
IQV leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
ITRM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ITRMIterum Therapeuti… | IQVIQVIA Holdings In… |
|---|---|---|
| Market CapShares × price | $2M | $29.9B |
| Enterprise ValueMkt cap + debt − cash | $23M | $44.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.02x | 22.51x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.89x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.56x |
| EV / EBITDAEnterprise value multiple | — | 12.87x |
| Price / SalesMarket cap ÷ Revenue | — | 1.84x |
| Price / BookPrice ÷ Book value/share | — | 4.62x |
| Price / FCFMarket cap ÷ FCF | — | 14.60x |
ITRM leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
IQV leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), IQV scores 4/9 vs ITRM's 1/9, reflecting mixed financial health.
| Metric | ITRMIterum Therapeuti… | IQVIQVIA Holdings In… |
|---|---|---|
| ROE (TTM)Return on equity | — | +22.1% |
| ROA (TTM)Return on assets | -74.8% | +4.7% |
| ROICReturn on invested capital | -117.8% | +8.7% |
| ROCEReturn on capital employed | -94.1% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 2.44x |
| Net DebtTotal debt minus cash | $21M | $14.2B |
| Cash & Equiv.Liquid assets | $24M | $2.0B |
| Total DebtShort + long-term debt | $46M | $16.2B |
| Interest CoverageEBIT ÷ Interest expense | -10.61x | 3.10x |
IQV leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IQV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IQV five years ago would be worth $7,632 today (with dividends reinvested), compared to $20 for ITRM. Over the past 12 months, IQV leads with a +20.7% total return vs ITRM's -96.9%. The 3-year compound annual growth rate (CAGR) favors IQV at -2.4% vs ITRM's -69.7% — a key indicator of consistent wealth creation.
| Metric | ITRMIterum Therapeuti… | IQVIQVIA Holdings In… |
|---|---|---|
| YTD ReturnYear-to-date | -90.2% | -21.7% |
| 1-Year ReturnPast 12 months | -96.9% | +20.7% |
| 3-Year ReturnCumulative with dividends | -97.2% | -7.0% |
| 5-Year ReturnCumulative with dividends | -99.8% | -23.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | +167.5% |
| CAGR (3Y)Annualised 3-year return | -69.7% | -2.4% |
IQV leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
IQV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IQV is the less volatile stock with a 1.33 beta — it tends to amplify market swings less than ITRM's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 71.4% from its 52-week high vs ITRM's 2.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ITRMIterum Therapeuti… | IQVIQVIA Holdings In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.49x | 1.33x |
| 52-Week HighHighest price in past year | $1.28 | $247.05 |
| 52-Week LowLowest price in past year | $0.03 | $134.65 |
| % of 52W HighCurrent price vs 52-week peak | +2.4% | +71.4% |
| RSI (14)Momentum oscillator 0–100 | 29.6 | 58.4 |
| Avg Volume (50D)Average daily shares traded | 35.4M | 1.6M |
IQV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ITRMIterum Therapeuti… | IQVIQVIA Holdings In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $225.63 |
| # AnalystsCovering analysts | — | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
IQV leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ITRM leads in 1 (Valuation Metrics).
Best OverallIQVIA Holdings Inc. (IQV)Leads 4 of 6 categories
Loading custom metrics...
ITRM vs IQV: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ITRM or IQV a better buy right now?
IQVIA Holdings Inc.
(IQV) offers the better valuation at 22. 5x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ITRM or IQV?
Over the past 5 years, IQVIA Holdings Inc.
(IQV) delivered a total return of -23. 7%, compared to -99. 8% for Iterum Therapeutics plc (ITRM). Over 10 years, the gap is even starker: IQV returned +167. 5% versus ITRM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ITRM or IQV?
By beta (market sensitivity over 5 years), IQVIA Holdings Inc.
(IQV) is the lower-risk stock at 1. 33β versus Iterum Therapeutics plc's 1. 49β — meaning ITRM is approximately 12% more volatile than IQV relative to the S&P 500.
04Which is growing faster — ITRM or IQV?
On earnings-per-share growth, the picture is similar: Iterum Therapeutics plc grew EPS 57.
4% year-over-year, compared to 4. 7% for IQVIA Holdings Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ITRM or IQV?
IQVIA Holdings Inc.
(IQV) is the more profitable company, earning 8. 3% net margin versus -69. 1% for Iterum Therapeutics plc — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -52. 0% for ITRM. At the gross margin level — before operating expenses — IQV leads at 26. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ITRM or IQV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ITRM or IQV better for a retirement portfolio?
For long-horizon retirement investors, IQVIA Holdings Inc.
(IQV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+167. 5% 10Y return). Both have compounded well over 10 years (IQV: +167. 5%, ITRM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ITRM and IQV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.